BioPorto Diagnostics is proud to announce a scientific poster presentation at the BRS/RA Conference in Manchester that includes data obtained with The NGAL Test - the company's forthcoming clinical chemistry test for the diagnosis and management of acute kidney injury.
The poster (P104) entitled "Urinary and plasma NGAL levels
reflect the severity of acute kidney injury" will be
on Thursday, May 20th between 11.30-12.30.
The BRS/RA Conference is a comprehensive discussion forum for all aspects of kidney care and renal research, organized by the British Renal Society in collaboration with the British Renal Association. BioPorto Diagnostics will be supporting Caltag Medsystems, its distribution partner in the United Kingdom, at the commercial exhibition. Meet Jakob Ohm Eriksen, Product Manager Pharma Diagnostics email@example.com at booth no. P19.
NGAL and The NGAL Test
NGAL is a novel biomarker for diagnosing acute kidney injury (AKI). The key advantage of NGAL is the early response to AKI and the proportionate response to injury.
The NGAL Test will be available for a wide range of clinical chemistry analyzers and is expected to be launched in the beginning of 2011. The NGAL Test will be able to determine NGAL levels in both urine and plasma within a standard routine timeframe.
For commercial enquiries, please contact Klaus Boberg Pedersen, Product Manager Human Diagnostics at firstname.lastname@example.org.